Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
268 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015', provides an overview of the Bile Duct Cancer (Cholangiocarcinoma)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bile Duct Cancer (Cholangiocarcinoma) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Bile Duct Cancer (Cholangiocarcinoma) Overview 8 Therapeutics Development 9 Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview 9 Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis 10 Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 11 Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 15 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 19 Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 22 Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 23 4SC AG 23 Agios Pharmaceuticals, Inc. 24 Ariad Pharmaceuticals, Inc. 25 ArQule, Inc. 26 Array BioPharma Inc. 27 Arrien Pharmaceuticals, LLC 28 AstraZeneca PLC 29 Bayer AG 30 Boston Biomedical, Inc. 31 Bristol-Myers Squibb Company 32 Celgene Corporation 33 CellAct Pharma GmbH 34 Concordia Healthcare Corp. 35 Cornerstone Pharmaceuticals, Inc. 36 Delcath Systems, Inc. 37 Eli Lilly and Company 38 Exelixis, Inc. 39 F. Hoffmann-La Roche Ltd. 40 GlaxoSmithKline Plc 41 Komipharm International Co., Ltd. 42 Mebiopharm Co., Ltd. 43 Merck & Co., Inc. 44 Merrimack Pharmaceuticals, Inc. 45 Novartis AG 46 NuCana BioMed Limited 47 OncoTherapy Science, Inc. 48 Panacea Pharmaceuticals, Inc. 49 PCI Biotech AS 50 Pfizer Inc. 51 Provecs Medical GmbH 52 Sanofi 53 Senhwa Biosciences, Inc. 54 Spectrum Pharmaceuticals, Inc. 55 Threshold Pharmaceuticals, Inc. 56 VasGene Therapeutics, Inc. 57 Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 58 Assessment by Monotherapy Products 58 Assessment by Combination Products 59 Assessment by Target 60 Assessment by Mechanism of Action 63 Assessment by Route of Administration 66 Assessment by Molecule Type 68 Drug Profiles 70 (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 70 AG-120 - Drug Profile 72 ARN-5032 - Drug Profile 74 ARQ-087 - Drug Profile 75 BBI-503 - Drug Profile 76 BGJ-398 - Drug Profile 78 binimetinib - Drug Profile 79 cabozantinib s-malate - Drug Profile 84 CAP-7.1 - Drug Profile 87 CC-90007 - Drug Profile 89 CPI-613 - Drug Profile 92 dasatinib - Drug Profile 94 DKN-01 - Drug Profile 97 elpamotide - Drug Profile 99 evofosfamide - Drug Profile 101 gemcitabine hydrochloride - Drug Profile 109 Im-01 - Drug Profile 110 KML-001 - Drug Profile 111 MBPY-005 - Drug Profile 113 melphalan - Drug Profile 114 merestinib - Drug Profile 116 MK-2206 - Drug Profile 117 NUC-1031 - Drug Profile 120 OCVC-01 - Drug Profile 122 paclitaxel albumin bound - Drug Profile 123 PAN-622 - Drug Profile 127 pembrolizumab - Drug Profile 128 ponatinib hydrochloride - Drug Profile 135 porfimer sodium - Drug Profile 137 Recombinant Protein to Antagonize EphB4 Receptor for Oncology - Drug Profile 138 refametinib - Drug Profile 140 regorafenib - Drug Profile 143 resminostat - Drug Profile 146 RRX-001 - Drug Profile 151 SAR-408701 - Drug Profile 153 selumetinib sulfate - Drug Profile 154 seribantumab - Drug Profile 157 silmitasertib - Drug Profile 160 SPI-1620 - Drug Profile 162 sunitinib malate - Drug Profile 163 trametinib dimethyl sulfoxide - Drug Profile 167 Vaccine for Metastatic Cholangiocarcinoma - Drug Profile 170 vemurafenib - Drug Profile 171 Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates 174 Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 253 Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 255 Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 256 Featured News & Press Releases 256 Appendix 264 Methodology 264 Coverage 264 Secondary Research 264 Primary Research 264 Expert Panel Validation 264 Contact Us 264 Disclaimer 265
List of Tables
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2015 12 Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2015 13 Number of Products under Development by Companies, H1 2015 15 Number of Products under Development by Companies, H1 2015 (Contd..1) 16 Number of Products under Development by Companies, H1 2015 (Contd..2) 17 Number of Products under Investigation by Universities/Institutes, H1 2015 18 Comparative Analysis by Late Stage Development, H1 2015 19 Comparative Analysis by Clinical Stage Development, H1 2015 20 Comparative Analysis by Early Stage Development, H1 2015 21 Products under Development by Companies, H1 2015 22 Products under Development by Companies, H1 2015 (Contd..1) 23 Products under Development by Companies, H1 2015 (Contd..2) 24 Products under Investigation by Universities/Institutes, H1 2015 25 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H1 2015 26 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals, Inc., H1 2015 27 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 28 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule, Inc., H1 2015 29 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc., H1 2015 30 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 31 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AstraZeneca PLC, H1 2015 32 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H1 2015 33 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical, Inc., H1 2015 34 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H1 2015 35 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corporation, H1 2015 36 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H1 2015 37 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Concordia Healthcare Corp., H1 2015 38 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 39 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems, Inc., H1 2015 40 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H1 2015 41 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis, Inc., H1 2015 42 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 43 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by GlaxoSmithKline Plc, H1 2015 44 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co., Ltd., H1 2015 45 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co., Ltd., H1 2015 46 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co., Inc., H1 2015 47 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 48 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H1 2015 49 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Limited, H1 2015 50 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science, Inc., H1 2015 51 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 52 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech AS, H1 2015 53 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc., H1 2015 54 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H1 2015 55 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H1 2015 56 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences, Inc., H1 2015 57 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 58 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 59 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics, Inc., H1 2015 60 Assessment by Monotherapy Products, H1 2015 61 Assessment by Combination Products, H1 2015 62 Number of Products by Stage and Target, H1 2015 64 Number of Products by Stage and Mechanism of Action, H1 2015 67 Number of Products by Stage and Route of Administration, H1 2015 70 Number of Products by Stage and Molecule Type, H1 2015 72 Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Recent Pipeline Updates, H1 2015 177 Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H1 2015 256 Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..1), H1 2015 257 Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H1 2015 258
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
